We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck’s Keytruda Receives Priority Reviews for Two New Carcinoma Indications
Merck’s Keytruda Receives Priority Reviews for Two New Carcinoma Indications
The FDA has granted Merck priority reviews for its blockbuster cancer drug Keytruda (pembrolizumab) alongside Lenvima (lenvatinib) for endometrial and renal cell carcinoma.